News | August 10, 2021
ALS drug RADICAVA holds promise as it completes four years in US
Nearly 6,000 patients have been treated with the drug since 2017
Nearly 6,000 patients have been treated with the drug since 2017
Deal signed with AOP Orphan for US commercial rights
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
The government has recently enhanced the incentive granted to storeowners from existing Rs. 2.50 lakh to Rs. 5.00 lakh given at the rate of 15% of monthly purchases made, subject to a ceiling of Rs. 15,000 per month
The goal for the project is the identification and optimization of anti-viral compounds.
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Subscribe To Our Newsletter & Stay Updated
